UNSPSC 51182434: Olpadronic acid

This classification denotes a bone resorption inhibitor with the molecular formula C5H15NO7P2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 874HHB2V3S, chemically known as phosphonic acid, (3-(dimethylamino)-1-hydroxypropylidene)bis- but generally known as olpadronic acid, which bears US NIH Compound Identifier 198716. European Medicines Agency schedules Olpadronic acid in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09432MIG.

The term OLPADRONIC ACID is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 9, No. 3, 1995, List 35). As of Q4 2014, OLPADRONIC ACID remains the US FDA Preferred Term for this commodity. Olpadronic acid bears US NLM identifiers UMLS ID C0285779 and NCI Concept Code C79878. SMILES: P(=O)(O)(O)C(P(=O)(O)O)(O)CCN(C)C.

UNSPSC 51182434 Olpadronic acid is a Commodity code that encompasses specialized pharmaceutical products supplied through multistate cooperative purchasing agreements to state and local government healthcare facilities. State and local governments procure under this code primarily as part of larger generic pharmaceutical and over-the-counter product frameworks managed through cooperative purchasing vehicles; olpadronic acid and related active pharmaceutical ingredients are bundled into broader pharmaceutical supply contracts rather than solicited individually. The issuing bodies are state purchasing offices and multistate cooperatives administering procurement on behalf of participating state agencies, local government facilities, and subordinate healthcare systems.

The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, posted an RFP on January 20, 2026 (due March 26, 2026) to establish multiple contracts for generic multi-source pharmaceuticals and OTC products across participating state and local government facilities, including Oregon. The procurement requires vendors to supply products through three authorized wholesalers—AmerisourceBergen Drug Corporation (Cencora), Cardinal Health 110 and 112, and Morris & Dickson Co., LLC—with awarded contracts effective July 1, 2026. Vendors must certify compliance with current Good Manufacturing Practices and the Drug Supply Chain Security Act, maintain relationships with at least two of the three wholesalers, and carry comprehensive insurance including $5,000,000 commercial general liability and $2,000,000 network security and privacy liability. The evaluation is weighted heavily toward price competitiveness (75 percent), with the remainder addressing fixed pricing, administrative compliance, EDI capability, and agreement to a 3 percent administrative fee. The contract term is two years for new responders, with possible extensions at MMCAP's discretion.